Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Brexogen Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 2 distinct art units. The busiest examiner is GONZALES, JOSEPHINE MARIA, who is responsible for 1 pending office action.
The 3 pending office actions are handled by different examiners, which indicates a lack of concentration in a single individual. The 2 distinct art units suggest that the biotechnology subject matter is divided between different specialized groups. Practitioners must manage these separate examiner relationships across the 2 distinct art units.
The presence of 3 distinct examiners for 3 pending office actions ensures that each matter receives an independent review. The practitioner must tailor responses to the specific preferences of GONZALES, JOSEPHINE MARIA and the other examiners within the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| COUNTS, GARY W | 1 | 58.9% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276218 | MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE | COUNTS, GARY W | 22d |
| 18945866 | COMPOSITION FOR PROMOTING PRODUCTION OF STEM CELL-DERIVED EXOSOMES AND INCREASING STEMNESS | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276218 | MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE | COUNTS, GARY W | 22d |
| 18945866 | COMPOSITION FOR PROMOTING PRODUCTION OF STEM CELL-DERIVED EXOSOMES AND INCREASING STEMNESS | GONZALES, JOSEPHINE MARIA | — |
| 18677400 | COMPOSITION FOR TREATMENT OF WOUNDS CONTAINING STEM CELL-DERIVED EXOSOMES AND METHOD FOR PREPARING SAME | STEVENS, MARK V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18945866 | COMPOSITION FOR PROMOTING PRODUCTION OF STEM CELL-DERIVED EXOSOMES AND INCREASING STEMNESS | GONZALES, JOSEPHINE MARIA | — | §103DP | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18677400 | COMPOSITION FOR TREATMENT OF WOUNDS CONTAINING STEM CELL-DERIVED EXOSOMES AND METHOD FOR PREPARING SAME | STEVENS, MARK V | 1613 | §102§103§112DP | Final Rejection | — | Pending | May 29, 2024 |
| 18276218 | MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE | COUNTS, GARY W | 1678 | §101§112 | Final Rejection | 22d | Pending | Aug 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial